Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background and purpose: There is increasing evidence that not only the monoaminergic but also the glutamatergic system is involved in the pathophysiology of attention‐deficit hyperactivity disorder (ADHD). Hyperactivity of glutamate metabolism might be causally related to a hypoactive state in the dopaminergic system. Atomoxetine, a selective noradrenaline reuptake inhibitor, is the first non‐stimulant approved for the treatment of this disorder. Here we have evaluated the effects of atomoxetine on glutamate receptors in vitro. Experimental approach: The whole‐cell configuration of the patch‐clamp technique was used to analyse the effect of atomoxetine on N‐methyl‐d‐aspartate (NMDA) receptors in cultured rodent cortical and hippocampal neurons as well as on NMDA receptors heterologously expressed in human TsA cells. Key results: Atomoxetine blocked NMDA‐induced membrane currents. Half‐maximal inhibition emerged at about 3 µM which is in the range of clinically relevant concentrations found in plasma of patients treated with this drug. The inhibition was voltage‐dependent, indicating an open‐channel blocking mechanism. Furthermore, the inhibitory potency of atomoxetine did not vary when measured on NMDA receptors from different brain regions or with different subunit compositions. Conclusions and implications: The effective NMDA receptor antagonism by atomoxetine at low micromolar concentrations may be relevant to its clinical effects in the treatment of ADHD. Our data provide further evidence that altered glutamatergic transmission might play a role in ADHD pathophysiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535 · cited 11×
“As these neurons mainly express the GluN2B subunit at this developmental stage (Szasz et al., 2007), we extended our experiments to a heterologous expression system in order to detect a possible difference in the sensitivity for GluN2A and GluN2B receptors.”
MethodInfluentialGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 1×
“Antidepressants have previously been shown to modulate glutamatergic neurotransmission, a mechanism that presumably contributes to the antidepressant effect (reviewed in Pittenger and Duman, 2008).”
BackgroundMolecular cloning and characterization of the rat NMDA receptor
Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N., & Nakanishi, S. (1991) · Nature · doi:10.1038/354031a0 · Cited by 1,771 · cited 5×
“For this purpose we tested heterologously expressed GluN1/GluN2A receptors using the extracellular low Ca2+ solution and a low agonist concentration (10 mM NMDA).”
MethodInfluentialMolina, B. S. G., Hinshaw, S. P., Swanson, J. M., Arnold, L. E., Vitiello, B., Jensen, P. S., Epstein, J. N., Hoza, B., Hechtman, L., Abikoff, H. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31819c23d0 · Cited by 1,182 · cited 1×
“In the 8 year follow-up of the Multimodal Treatment study of children with ADHD (n = 487), some children showed substantial long-term benefit from medication while others showed little improvement (Molina et al., 2009).”
BackgroundFINDLING, R. L., SHORT, E. J., McNAMARA, N. K., DEMETER, C. A., STANSBREY, R. J., GRACIOUS, B. L., WHIPKEY, R., MANOS, M. J., & CALABRESE, J. R. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31814b8d3b · Cited by 120 · cited 2×
“Memantine, an uncompetitive NMDA receptor antagonist used for the treatment of Alzheimer’s disease, was evaluated in an open-label pilot study for its effectiveness in paediatric patients with ADHD (Findling et al., 2007b).”
BackgroundMethodInfluentialStriatal Creatine and Glutamate/Glutamine in Attention-Deficit/Hyperactivity Disorder
Carrey, N. J., MacMaster, F. P., Gaudet, L., & Schmidt, M. H. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.0008 · Cited by 117 · cited 2×
“In the last years, preclinical and clinical data emerged that also alterations in other neurotransmitter systems, especially interactions with glutamate metabolism, might play a role in the pathophysiology of this highly prevalent and impairing disorder (Carrey et al., 2007; Lulé et al., 2008).”
BackgroundGilbert, D. L., Ridel, K. R., Sallee, F. R., Zhang, J., Lipps, T. D., & Wassermann, E. M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300806 · Cited by 97
Cited by
Agmatine rescues autistic behaviors in the valproic acid-induced animal model of autism
Kim, J.-W., Seung, H., Kim, K. C., Gonzales, E. L. T., Oh, H. A., Yang, S. M., Ko, M. J., Han, S.-H., Banerjee, S., & Shin, C. Y. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.014 · Cited by 102
“…has been known to inhibit norepinephrine and dopamine transporters and increase norepinephrine and dopamine availability in the post-synapse (Bymaster et al., 2002; Swanson et al., 2006) but it was also recently found to block NMDA currents through NMDA receptor antagonism (Ludolph et al., 2010).”
Adults with Attention-Deficit/Hyperactivity Disorder ? A Brain Magnetic Resonance Spectroscopy Study
Dramsdahl, M., Ersland, L., Plessen, K. J., Haavik, J., Hugdahl, K., & Specht, K. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00065 · Cited by 43
“A recent study (Ludolph et al., 2010) highlights the role of glutamate in ADHD by demonstrating that the norepinephrine reuptake inhibitor atomoxetine, which is effective against ADHD symptoms, is also an NMDA receptor antagonist.”
BackgroundHusarova, V., Bittsansky, M., Ondrejka, I., & Dobrota, D. (2014) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2014.03.003 · Cited by 19
Metadata
- Authors
- Ludolph, A. G., Udvardi, P. T., Schaz, U., Henes, C., Adolph, O., Weigt, H. U., Fegert, J. M., Boeckers, T. M., & Föhr, K. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-04-26
- Volume
- 160
- Issue
- 2
- Pages
- 283-291
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1530918435
- Cited by
- 82
- References
- 9
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.00707.x
- The paper
- Ludolph, A. G., Udvardi, P. T., Schaz, U., Henes, C., Adolph, O., Weigt, H. U., Fegert, J. M., Boeckers, T. M., & Föhr, K. J. (2010). Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.00707.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.